Skip to main content

Table 2 Characteristics of HIV infected pregnant women, USA versus Europe: disease progression and treatment

From: Characteristics and management of HIV-1-infected pregnant women enrolled in a randomised trial: differences between Europe and the USA

Characteristic

USA

Europe

Overall

P-value

Median CD4 count: entry (IQR)

437 (293–600)

420 (299–568)

430 (294–592)

0.6958

<200 cells per ml

124 (13%)

37 (10%)

161 (12%)

 

200–499

294 (30%)

132 (35%)

426 (32%)

 

≥500

560 (57%)

203 (55%)

763 (57%)

 

Median HIV RNA: entry (IQR)

581 (274–3635)

700 (200–4740)

594 (243–3845)

0.1225

≤400 copies/ml

424 (43%)

142 (38%)

566 (42%)

 

400–2,499

252 (26%)

92 (24%)

344 (25%)

 

2,500–10,000

143 (15%)

62 (17%)

205 (15%)

 

>10,000

138 (14%)

57 (15%)

195 (14%)

 

Median CD4 count: delivery (IQR)

480 (308–658)

444 (320–632)

469 (310–653)

0.6849

<200 cells/ml

103 (12%)

26 (8%)

129 (11%)

 

200–499

233 (27%)

109 (34%)

342 (29%)

 

≥500

531 (61%)

187 (58%)

718 (60%)

 

Median HIV RNA: delivery (IQR)

405 (237–2638)

200 (68–1300)

400 (200–2300)

0.0001

≤400 copies/ml

450 (50%)

176 (64%)

626 (53%)

 

400–2,499

220 (24%)

49 (18%)

269 (23%)

 

2,500–10,000

115 (13%)

36 (14%)

151 (13%)

 

>10,000

116 (13%)

16 (6%)

132 (11%)

 

Maternal ARV use

   

<0.0001

HAART

448 (46%)

119 (32%)

567 (42%)

 

Dual therapy

342 (35%)

132 (35%)

474 (35%)

 

Monotherapy

182 (19%)

119 (32%)

301 (22%)

 

No ARV

6 (0.6%)

2 (0.5%)

8 (0.6%)

 

Timing of ARV initiation

   

0.0001

Pre-pregnancy

357 (37%)

182 (49%)

539 (40%)

 

During pregnancy

606 (63%)

190 (51%)

796 (60%)

 

Symptomatic HIV disease at entry

   

0.0194

Yes

74 (8%)

15 (4%)

89 (7%)

 

No

904 (92%)

357 (96%)

1261 (93%)

Â